Abcentra, LLC

Christopher John Farina

Stacey Ruiz

Bertrand C Liang

Jan Nilsson

Ryan Benjamin Abbott

Compositions and methods for treating rheumatoid arthritis and/or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.

Methods for treatment of accelerated atherosclerosis and rheumatoid arthritis with an anti-Apo B100 antibody

Compositions and methods for treating a subject with psoriasis are provided, including an inhibitor of oxidized low density lipoprotein (LDL), malondialdehyde-modified epitope in LDL or native LDL for administration. Exemplary inhibitors of oxidized or malondialdehyde-modified LDL include orticumab, a variant antibody or peptides capable of binding oxidized or malondialdehyde-modified LDL, which results in improvement in conditions of psoriasis even in patients that are refractory to ultraviolet A/B therapy and topical steroids.

Methods for treatment of psoriasis with an anti-Apo B100 antibody

Methods for treatment of rheumatoid arthritis and accelerated atherosclerosis with an anti-Apo B100 antibody

Described herein are peptides and antibodies for prevention and/or therapeutic treatment of mammals, including humans, against systemic lupus erythematosus, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing SLE and/or to disease grading, staging, and/or prognosis.

Growing community of inventors

Los Angeles, CA, United States of America

Christopher John Farina